期刊
JOURNAL OF CONTROLLED RELEASE
卷 353, 期 -, 页码 563-590出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2022.11.057
关键词
Myocardial ischemia-reperfusion injury; Nanomedicine; Therapy; Imaging; Theranostic
Myocardial ischemia-reperfusion injury (IRI) is a common cardiovascular disease caused by the restoration of blood flow to the ischemic myocardium. Nanomedicines have shown great potential in the diagnosis and treatment of myocardial IRI due to their advantageous properties. This review focuses on the rational design of nanomedicines for optimal imaging and therapy of myocardial IRI.
Myocardial ischemia-reperfusion injury (IRI) is becoming a typical cardiovascular disease with increasing worldwide incidence. It is usually induced by the restoration of normal blood flow to the ischemic myocardium after a period of recanalization and directly leads to myocardial damage. Notably, the pathological mechanism of myocardial IRI is closely related to inflammation, oxidative stress, Ca2+ overload, and the opening of mito-chondrial permeability transition pore channels. Therefore, monitoring of these changes and imaging lesions is a key to timely clinical diagnosis. Nanomedicines have shown great value in the diagnosis and treatment of myocardial IRI, with advantages including passive/active targeting, prolonged circulation, improved bioavail-ability, versatile carrier selection, and synergistic integration of different imaging and therapeutic agents in single particles with the same pharmaceutics. Because theranostic nanomedicines for myocardial IRI have advanced rapidly, we conduct an updated review on this topic. The special focus is on how to rationally design the nanomedicines to achieve optimal imaging and therapy. We hope this review would stimulate the interest of researchers with different backgrounds and expedite the development of nanomedicines for myocardial IRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据